At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

Discover how in some communities around the world, the prevalence of rare diseases is higher due to factors like cousin ...

Gene therapies have seen a drop in investor interest lately. Despite this, Kriya Therapeutics seems to be attracting funds in ...

Once thought to be under control, yellow fever is making an alarming comeback, and the numbers are climbing. With treatment ...

Learn how multichain biotherapeutics overcome manufacturing challenges with advanced expression vector design.

As the release of a CRL declining Lykos' therapy generates a strong reaction from MAPS, delve into what this new transparency ...

As in July, there were six major merger and acquisition (M&A) deals that were inked during the month of August. Pharma giant AbbVie’s $1.2 billion buyout of American biotech Gilgamesh Pharmaceuticals’ ...

Explore innovations in antimalarial drug discovery, from screening and compound design to resistance mechanisms and PK optimization.

Two months after ExCellThera’s Zemcelpro (UM171 cell therapy) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), the European ...

Nature writes the best horror stories – In The New York Times’ recent piece, the return of the screwworm, a flesh‑eating parasite once eradicated from the U.S. Indeed, cattle ranchers are once again ...